STEVENSVILLE, Md., March 14 /PRNewswire/ -- Vapotherm Inc., a privately held manufacturer of respiratory care devices for hospital and home care use, today announced that European patent rights have been validated in six European countries for Vapotherm’s apparatus and method for respiratory tract therapy. European Patent No. 1 237 614 has now been validated in Germany, France, Spain, Portugal, Italy and Austria.
An integral component of the company’s HFT(TM) brand High Flow Therapy(TM) Humidification System, the VAPOTHERM(R) Patient Delivery Tube system enables maintenance of breathing gas temperature by circulating water through a triple lumen, minimizing condensation and eliminating the need for heated wire circuits.
“We are pleased that these European rights have been validated in six European countries for this component which is central to the safe and effective delivery of breathing gases via the VAPOTHERM(R) HFNC(TM) brand High Flow Nasal Cannula(TM) or approved interface,” said William Niland, Chairman and Director of New Product Development.
“These patent validation announcements coincide with our recent launches in major European markets including Germany, France and Spain where we are now partnered with the leading local respiratory product distributors,” said Kevin Thibodeau, Vice President of Sales and Marketing.
Vapotherm, Inc. is dedicated to the development of unique, medical gas delivery technologies for respiratory airway therapies, especially for the treatment of chronic lung and acute breathing disorders. The Company’s 2000i respiratory gas humidification device is distributed worldwide. For more information, visit http://www.vtherm.com.
Media contact: Kevin Thibodeau Vapotherm, Inc. VP, Sales and Marketing (410) 604-3977
Vapotherm, Inc.
CONTACT: Kevin Thibodeau, VP, Sales and Marketing of Vapotherm, Inc.,+1-410-604-3977
Web site: http://www.vtherm.com//
